RecruitingNCT06305611

European and North Indian Cohort of KaWasaki dIsease

Comparison and Performance of Kobayashi and Kawanet IVIg Resistance Scores in a Multi-centric European and North Indian Cohort of KaWasaki dIsease (the KIWI Study)


Sponsor

Meyer Children's Hospital IRCCS

Enrollment

103 participants

Start Date

Jul 13, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Kawasaki disease (KD) is currently the leading cause of acquired heart diseases in children in developed countries. Cardiac involvement is the main determinant of the long-term prognosis of these patients, as coronary aneurisms (CAAs) may lead to ischemic heart disease and even sudden death. The current standard of care for KD has consistently reduced CAAs frequency from 25-30% to about 5%. Unfortunately, 10-20% of KD patients results resistant to standard treatment leading to a major risk of cardiac complications. Thus, scoring systems have been constructed in order to identify patients likely to be resistant to IVIG and who may benefit from more aggressive initial therapy. Different scoring scales developed by Kobayashi, Egami et Sano had shown a good sensitivity (77-86%) and specificity (67-86%) in predicting IVIG unresponsiveness in Japanese populations. However, their predictive value was not confirmed by subsequent studies in different ethnic populations. Recently, the French Kawanet group have proposed a IVIG unresponsiveness score that provided good sensitivity and acceptable specificity in a non-Asian KD population even if it was not subsequent validated by an external study. In our study population, the achievement of specificity and sensitivity values for both scores consistent with those reported by the original studies (sensitivity 70% and specificity 80% for Kobayashi and sensitivity 77% and specificity 60% for Kawanet), will be considered a success.


Eligibility

Min Age: 1 YearMax Age: 17 Years

Inclusion Criteria2

  • Patients aged less than 18 years at diagnosis
  • Diagnosis of KD according to the AHA criteria

Exclusion Criteria2

  • Patients who do not meet the criteria for KD
  • Patients for which an alternative infectious diagnosis was not investigated and/or excluded.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(27)

Universidade Federal do Rio de Janeiro

Rio de Janeiro, Brazil

Children's Hospital Zagreb

Zagreb, Croatia

University Hospital Centre Zagreb, University School of Medicine

Zagreb, Croatia

Le Kremlin-Bicetre University Hospital, Paris-Sud University - CEREMAI

Le Kremlin-Bicêtre, France

Manipal Hospital

Bangalore, India

Postgraduate Institute of Medical Education and Research

Chandigarh, India

Sri Ramachandra Medical Centre

Chennai, India

Amrita Institute of Medical Sciences

Kochi, India

Institute of Child Health

Kolkata, India

Vivekananda Institute of Medical Sciences

Kolkata, India

Meir Medical Centre

Kfar Saba, Israel

ASST Papa Giovanni XXIII

Bergamo, Italy

Spedali Civili

Brescia, Italy

Meyer Children's Hospital IRCCS

Florence, Italy

IRCCS Istituto Giannina Gaslini

Genova, Italy

Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico

Milan, Italy

P.O. "Giovanni Di Cristina"

Palermo, Italy

Università di Torino

Torino, Italy

IRCCS Burlo Garofolo

Trieste, Italy

Beatrix Kinderkliniek, University Medical Center

Groningen, Netherlands

Hospital de Sabadell

Barcelona, Spain

Hospital Sant Joan de Déu

Barcelona, Spain

Chiang Mai University Hospital

Chiang Mai, Thailand

Hacettepe University Children's Hospital

Ankara, Turkey (Türkiye)

Health Sciences University, Umraniye Education and Research Hospital

Istanbul, Turkey (Türkiye)

Istanbul Uni. Istanbul Med.Fac

Istanbul, Turkey (Türkiye)

Royal Hospital for Children

Bristol, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06305611


Related Trials